# Evommune Inc. (EVMN)

Source: https://www.quantisnow.com/company/EVMN
Generated: 2026-11-21T00:49:18.425Z

- Ticker: EVMN
- Exchange: NYSE
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2025
- SEC CIK: 0002044725

## Latest EVMN news and filings

- 2026-11-17 21:41 UTC [SEC Form 4] [Director Arthur S Kirsch returned 53,633 stock options to the company and was granted 53,633 stock options (SEC Form 4)](https://www.quantisnow.com/insight/director-arthur-s-kirsch-returned-53633-stock-options-to-the-6797107)
- 2026-11-17 21:40 UTC [SEC Form 4] [Director David E Cohen returned 53,633 stock options to the company and was granted 53,633 stock options (SEC Form 4)](https://www.quantisnow.com/insight/director-david-e-cohen-returned-53633-stock-options-to-the-6797097)
- 2026-11-17 21:40 UTC [SEC Form 4] [Director Benjamin F Mcgraw III returned 53,633 stock options to the company and was granted 53,633 stock options (SEC Form 4)](https://www.quantisnow.com/insight/director-benjamin-f-mcgraw-iii-returned-53633-stock-options-to-6797094)
- 2026-11-17 21:39 UTC [SEC Form 4] [Chief of Dev. Operations Janice Suzann Drew returned 305,166 stock options to the company and was granted 305,166 stock options (SEC Form 4)](https://www.quantisnow.com/insight/chief-of-dev-operations-janice-suzann-drew-returned-305166-stock-6797090)
- 2026-11-17 21:39 UTC [SEC Form 4] [Chief Scientific Officer Jeegar Pravinkumar Patel returned 248,934 stock options to the company and was granted 248,934 stock options (SEC Form 4)](https://www.quantisnow.com/insight/chief-scientific-officer-jeegar-pravinkumar-patel-returned-248934-stock-options-6797086)
- 2026-11-17 21:39 UTC [SEC Form 4] [Chief Financial Officer Kyle Carver returned 378,354 stock options to the company and was granted 378,354 stock options (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-kyle-carver-returned-378354-stock-options-to-6797085)
- 2026-11-17 21:38 UTC [SEC Form 4] [Chief Business & Legal Officer Gregory S. Moss returned 408,775 stock options to the company and was granted 408,775 stock options (SEC Form 4)](https://www.quantisnow.com/insight/chief-business-legal-officer-gregory-s-moss-returned-408775-stock-6797080)
- 2026-11-17 21:37 UTC [SEC Form 4] [Chief Medical Officer Eugene Bauer returned 151,117 stock options to the company and was granted 151,117 stock options (SEC Form 4)](https://www.quantisnow.com/insight/chief-medical-officer-eugene-bauer-returned-151117-stock-options-to-6797076)
- 2026-11-17 21:37 UTC [SEC Form 4] [President & CEO Luis C. Pena returned 1,088,261 stock options to the company and was granted 1,088,261 stock options (SEC Form 4)](https://www.quantisnow.com/insight/president-ceo-luis-c-pena-returned-1088261-stock-options-to-6797072)
- 2026-11-17 21:35 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Evommune Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-evommune-inc-6797037)
- 2026-11-17 21:30 UTC [SEC Form 8-K] [Evommune Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/evommune-inc-filed-sec-form-8-k-leadership-update-6796939)
- 2026-11-16 15:00 UTC [SEC Schedule 13G] [Amendment: SEC Form SCHEDULE 13G/A filed by Evommune Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-evommune-inc-6792978)
- 2026-11-12 21:23 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Evommune Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-evommune-inc-6788274)
- 2026-11-12 21:10 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Evommune Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-evommune-inc-6787962)
- 2026-11-12 21:06 UTC [SEC Form 8-K] [Evommune Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/evommune-inc-filed-sec-form-8-k-results-of-operations-and-6787841)
- 2026-11-12 21:05 UTC [Earnings] [Evommune Reports Third Quarter 2026 Financial Results and Provides Business Highlights](https://www.quantisnow.com/insight/evommune-reports-third-quarter-2026-financial-results-and-provides-business-6787666)
- 2026-11-10 21:45 UTC [SEC Schedule 13D] [Amendment: SEC Form SCHEDULE 13D/A filed by Evommune Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-evommune-inc-6784500)
- 2026-11-09 13:05 UTC [Conference Announcement] [Evommune to Present at Upcoming Investor Conferences](https://www.quantisnow.com/insight/evommune-to-present-at-upcoming-investor-conferences-6780417)
- 2026-11-05 11:32 UTC [SEC Form 8-K] [Evommune Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/evommune-inc-filed-sec-form-8-k-regulation-fd-disclosure-financial-6774230)
- 2026-11-05 11:30 UTC [Evommune Announces Webcast Discussing EVO570 and Its Expanding Immunology Portfolio Today at 8:30 a.m. ET](https://www.quantisnow.com/insight/evommune-announces-webcast-discussing-evo570-and-its-expanding-immunology-portfolio-6774198)
- 2026-11-04 22:15 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Evommune Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-evommune-inc-6773581)
- 2026-11-04 22:10 UTC [SEC Form 8-K] [Evommune Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/evommune-inc-filed-sec-form-8-k-entry-into-a-material-6773548)
- 2026-11-04 22:10 UTC [Evommune Announces $30 Million Private Placement](https://www.quantisnow.com/insight/evommune-announces-30-million-private-placement-6773532)
- 2026-11-04 22:02 UTC [Evommune Enters into Agreement to In-License EVO570, a Potential Best-in-Class Oral VAV1 Molecular Glue Degrader, from Hinova Pharmaceuticals](https://www.quantisnow.com/insight/evommune-enters-into-agreement-to-in-license-evo570-a-potential-best-in-class-6773456)
- 2026-10-20 11:36 UTC [Analyst Coverage Resumed] [Morgan Stanley resumed coverage on Evommune with a new price target](https://www.quantisnow.com/insight/morgan-stanley-resumed-coverage-on-evommune-with-a-new-price-6751430)
- 2026-10-15 20:28 UTC [SEC Form 4] [SEC Form 4 filed by Evommune Inc.](https://www.quantisnow.com/insight/sec-form-4-filed-by-evommune-inc-6748204)
- 2026-10-12 12:49 UTC [Analyst Coverage Initiated] [UBS initiated coverage on Evommune with a new price target](https://www.quantisnow.com/insight/ubs-initiated-coverage-on-evommune-with-a-new-price-target-6743587)
- 2026-10-01 12:01 UTC [SEC Form 8-K] [Evommune Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/evommune-inc-filed-sec-form-8-k-regulation-fd-disclosure-financial-6731521)
- 2026-10-01 12:00 UTC [Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress](https://www.quantisnow.com/insight/evommune-presents-late-breaking-phase-2a-proof-of-concept-data-evaluating-evo301-in-6731462)
- 2026-09-23 20:05 UTC [SEC Form 8-K] [Evommune Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/evommune-inc-filed-sec-form-8-k-regulation-fd-disclosure-financial-6724142)
- 2026-09-23 20:05 UTC [Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress](https://www.quantisnow.com/insight/evommune-announces-late-breaker-presentation-of-phase-2a-data-for-evo301-6724127)
- 2026-09-15 12:30 UTC [SEC Form 8-K] [Evommune Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/evommune-inc-filed-sec-form-8-k-regulation-fd-disclosure-financial-6715525)
- 2026-09-08 21:43 UTC [Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis](https://www.quantisnow.com/insight/evommune-announces-top-line-results-from-evo756-phase-2b-trial-in-6708787)
- 2026-08-26 12:24 UTC [Analyst Coverage Initiated] [Needham initiated coverage on Evommune with a new price target](https://www.quantisnow.com/insight/needham-initiated-coverage-on-evommune-with-a-new-price-target-6695075)
- 2026-08-14 20:17 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Evommune Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-evommune-inc-6683015)
- 2026-08-14 14:38 UTC [SEC Form SCHEDULE 13G filed by Evommune Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-evommune-inc-6682300)
- 2026-08-06 20:10 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Evommune Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-evommune-inc-6669043)
- 2026-08-06 20:09 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Evommune Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-evommune-inc-6669016)
- 2026-08-06 20:06 UTC [SEC Form 8-K] [Evommune Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/evommune-inc-filed-sec-form-8-k-results-of-operations-and-6668864)
- 2026-08-06 20:05 UTC [Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights](https://www.quantisnow.com/insight/evommune-reports-second-quarter-2026-financial-results-and-provides-business-6668630)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/EVMN
- Earnings history: https://www.quantisnow.com/earnings/EVMN
- Dividend history: https://www.quantisnow.com/dividends/EVMN
- Insider transactions: https://www.quantisnow.com/insiders/EVMN
- Options chain: https://www.quantisnow.com/options/EVMN
- SEC 8-K filings only: https://www.quantisnow.com/company/EVMN/8-k
- RSS and alerts for EVMN: https://www.quantisnow.com/docs/rss-feeds.md
